Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal is aimed at bolstering Celgene’s portfolio of cancer drugs. The deal is expected to be neutral to Celgene’s earnings in 2010 and accretive in 2011. Gloucester, founded in [...] (CELG) Celgene Corporation Expands into Cancer Drugs